ID   HMC-1.3 clone 2E2
AC   CVCL_E8DW
DR   ABM; T8389
DR   GEO; GSM6674140
DR   GEO; GSM6674141
DR   GEO; GSM6674142
RX   PubMed=37025992;
CC   Characteristics: Compared to the parent cell line has reduced activity in pathways involved in survival, cell-to-cell adhesion, and neoplasia with differences in expression of molecular components and cell surface markers (PubMed=37025992).
CC   Characteristics: Produces significantly smaller tumors than the parent cell line when subcutaneously inoculated in mice (PubMed=37025992).
CC   Doubling time: 36-48 hours (ABM=T8389).
CC   Sequence variation: Mutation; HGNC; HGNC:6342; KIT; Simple_corrected; p.Val560Gly (c.1679T>G); ClinVar=VCV000375916; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=37025992).
CC   Sequence variation: Mutation; HGNC; HGNC:6342; KIT; Simple; p.Asp816Val (c.2447A>T); ClinVar=VCV000013852; Zygosity=Heterozygous (PubMed=37025992).
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: Mast cell; CL=CL_0000097.
DI   NCIt; C3169; Mast cell leukemia
DI   ORDO; Orphanet_98851; Mast cell leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_H205 ! HMC-1.2
SX   Male
AG   52Y
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=37025992; DOI=10.3389/fimmu.2023.1078958; PMCID=PMC10071028;
RA   Bandara G., Falduto G.H., Luker A.J., Bai Y., Pfeiffer A., Lack J.B.,
RA   Metcalfe D.D., Olivera A.;
RT   "CRISPR/Cas9-engineering of HMC-1.2 cells renders a human mast cell
RT   line with a single D816V-KIT mutation: an improved preclinical model
RT   for research on mastocytosis.";
RL   Front. Immunol. 14:1078958.1-1078958.17(2023).
//